SCM
NRIX icon

Soleus Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Soleus Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.5M Buy
1,465,163
+527,000
+56% +$8.98M 1.22% 24
2026
Q1 		$14.5M Sell
938,163
-281,231
-23% -$4.66M 0.59% 42
2025
Q4 		$23.1M Sell
1,219,394
-1,203,439
-50% -$17.3M 0.85% 36
2025
Q3 		$22.4M Hold
2,422,833
– – 1.13% 26
2025
Q2 		$27.6M Hold
2,422,833
– – 1.83% 16
2025
Q1 		$28.8M Buy
2,422,833
+320,000
+15% +$5.35M 2.07% 13
2024
Q4 		$39.6M Buy
2,102,833
+1,036,999
+97% +$23.8M 2.49% 12
2024
Q3 		$23.9M Sell
1,065,834
-990,082
-48% -$22.4M 1.85% 18
2024
Q2 		$42.9M Buy
2,055,916
+940,916
+84% +$14.7M 3.78% 4
2024
Q1 		$16.4M Buy
1,115,000
+972,000
+680% +$10.5M 1.22% 24
2023
Q4 		$1.48M Sell
143,000
-671,000
-82% -$4.6M 0.16% 59
2023
Q3 		$6.4M Buy
+814,000
New +$7.43M 0.59% 46
2022
Q4 		– Sell
-504,144
Closed -$6.57M – 84
2022
Q3 		$6.57M Sell
504,144
-490,348
-49% -$7.76M 0.89% 33
2022
Q2 		$12.6M Sell
994,492
-17,146
-2% -$194K 1.97% 17
2022
Q1 		$14.2M Buy
1,011,638
+268,400
+36% +$4.76M 1.83% 20
2021
Q4 		$21.5M Buy
743,238
+479,338
+182% +$14.5M 2.15% 13
2021
Q3 		$7.91M Buy
+263,900
New +$8.14M 1.23% 26

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Soleus Capital Management's NRIX Position: Q2 2026 in Review

Soleus Capital Management increased its Nurix Therapeutics (NRIX) stake by 56% in Q2 2026, buying an estimated $8.98M and bringing the position to 1,465,163 shares worth $35.5M. The position accounts for 1.22% of the portfolio, ranked #24.

Soleus Capital Management first reported a position in NRIX in Q3 2021 and has held it in 17 quarters since. The position peaked at $42.9M in Q2 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Soleus Capital Management held 1,465,163 shares of Nurix Therapeutics worth $35.5M as of Q2 2026.
  • Soleus Capital Management bought 527,000 Nurix Therapeutics shares in Q2 2026, an estimated $8.98M.
  • Nurix Therapeutics made up 1.22% of Soleus Capital Management's portfolio in Q2 2026, its #24 holding.
  • Soleus Capital Management first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Soleus Capital Management's Nurix Therapeutics position peaked at $42.9M in Q2 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.